Vedolizumab vs. ustekinumab as second-line therapy in Crohn’s disease in clinical practice

Vedolizumab vs. ustekinumab as second-line therapy in Crohn’s disease in clinical practice

Kolar M, Duricova D, Bortlik M, Pudilova K, Hruba V, Machkova N, Mitrova K, Malickova K, Lukas M, Vasatko M, Vanickova R, Lukas M: Vedolizumab vs. ustekinumab as second-line therapy in Crohn’s disease in clinical practice. Gastroenterologie a Hepatologie 2019, 73(1):25-31.

Odkaz na článek (GaH)

Další publikace

Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis – results from multicenter observational cohort
Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis – results from multicenter observational
cohort
přejít na článek
Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort
Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide
cohort
přejít na článek
Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre
Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases
Centre
přejít na článek
Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation
Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective
observation
přejít na článek
Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis
Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative
Colitis
přejít na článek
Tofacitinib induction efficacy and safety in ulcerative colitis at week 8 – results from clinical practice
Tofacitinib induction efficacy and safety in ulcerative colitis at week 8 – results from clinical
practice
přejít na článek
Telemedicine and inflammatory bowel disease – results of the IBD Assistant pilot project
Telemedicine and inflammatory bowel disease – results of the IBD Assistant pilot
project
přejít na článek
Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases
Biosimilars: concept, current status, and future perspectives in inflammatory bowel
diseases
přejít na článek
POCT system for the fecal calprotectin detection in the telemonitoring of patients with inflammatory bowel disease
POCT system for the fecal calprotectin detection in the telemonitoring of patients with inflammatory bowel
disease
přejít na článek
Early vedolizumab trough levels are not associated with short-term response in patients with inflammatory bowel disease
Early vedolizumab trough levels are not associated with short-term response in patients with inflammatory bowel
disease
přejít na článek
The efficacy and safety of budesonide MMX (Cortiment®) for long-term maintenance therapy of ulcerative colitis
The efficacy and safety of budesonide MMX (Cortiment®) for long-term maintenance therapy of ulcerative
colitis
přejít na článek
Pregnancy outcomes in women with IBD treated with biosimilar infliximab
Pregnancy outcomes in women with IBD treated with biosimilar
infliximab
přejít na článek
Fecal zonulin is elevated in Crohn’s disease and in cigarette smokers
Fecal zonulin is elevated in Crohn’s disease and in cigarette
smokers
přejít na článek
Biosimilar infliximab in anti-TNF naïve IBD patients – 1-year clinical follow-up
Biosimilar infliximab in anti-TNF naïve IBD patients – 1-year clinical
follow-up
přejít na článek
Budesonide MMX (Cortiment® 9 mg) in the treatment of ulcerative colitis in real clinical practice
Budesonide MMX (Cortiment® 9 mg) in the treatment of ulcerative colitis in real clinical
practice
přejít na článek
Anti-SARS-CoV-2 antibody testing in IBD healthcare professionals: are we currently able to provide COVID-free IBD clinics
Anti-SARS-CoV-2 antibody testing in IBD healthcare professionals: are we currently able to provide COVID-free IBD
clinics
přejít na článek
Testování COVID-19-co bychom měli mít na paměti
Testování COVID-19-co bychom měli mít na
paměti
přejít na článek
Evaluation of Infliximab Therapy in Children with Crohn’s Disease Using Trough Levels Predictors
Evaluation of Infliximab Therapy in Children with Crohn’s Disease Using Trough Levels
Predictors
přejít na článek
The role of steroid hormones in the development of intrahepatic cholestasis of pregnancy
The role of steroid hormones in the development of intrahepatic cholestasis of
pregnancy
přejít na článek
Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease. Biologicals
Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease.
Biologicals
přejít na článek